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BACKGROUND: Tumours contain hypoxic regions that select for an aggressive cell phenotype; tumour hypoxia induces metastasis-
associated genes. Treatment refractory patients with metastatic cancer show increased numbers of circulating tumour cells (CTCs),
which are also associated with disease progression. The aim of this study was to examine the as yet unknown relationship between
hypoxia and CTCs.
METHODS: We generated human MDA-MB-231 orthotopic xenografts and, using a new technology, isolated viable human CTCs from
murine blood. The CTCs and parental MDA-MB-231 cells were incubated at 21 and 0.2% (hypoxia) oxygen, respectively. Colony
formation was assayed and levels of hypoxia- and anoxia-inducible factors were measured. Xenografts generated from CTCs and
parental cells were compared.
RESULTS: MDA-MB-231 xenografts used to generate CTCs were hypoxic, expressing hypoxia factors: hypoxia-inducible factor1 alpha
(HIF1a) and glucose transporter protein type 1 (GLUT1), and anoxia-induced factors: activating transcription factor 3 and 4 (ATF3
and ATF4). Parental MDA-MB-231 cells induced ATF3 in hypoxia, whereas CTCs expressed it constitutively. Asparagine synthetase
(ASNS) expression was also higher in CTCs. Hypoxia induced ATF4 and the HIF1a target gene apelin in CTCs, but not in parental
cells. Hypoxia induced lower levels of carbonic anhydrase IX (CAIX), GLUT1 and BCL2/adenovirus E1B 19-KD protein-interacting
protein 3 (BNIP3) proteins in CTCs than in parental cells, supporting an altered hypoxia response. In chronic hypoxia, CTCs
demonstrated greater colony formation than parental cells. Xenografts generated from CTCs were larger and heavier, and
metastasised faster than MDA-MB-231 xenografts.
CONCLUSION: CTCs show an altered hypoxia response and an enhanced aggressive phenotype in vitro and in vivo.
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Metastasis is a multi-step process leading to the spread of
neoplastic cells to distant sites. Circulating tumour cells (CTCs)
have been detected in the peripheral blood of cancer patients and
provide an index of disease aggression in patients with distant
metastasis (Dawood et al, 2008). During the metastatic process,
CTCs are generated from primary tumour, and subsequently
invade and colonise distant organs (Gupta and Massague, 2006).
Tumours are heterogeneous and contain regions of hypoxia and
anoxia, which may select for cells with more aggressive phenotypes
and diminished apoptotic potential (Graeber et al, 1996; Zhang
and Hill, 2004). The tumour hypoxic microenvironment con-
tributes to increased metastases by regulating the number of genes
that are implicated in the metastatic process. Clinical evidence also
suggests that patients with tumours that contain more extensive
hypoxic and anoxic areas have higher rates of metastases (Brizel
et al, 1996). Therefore, tumour hypoxia and anoxia may be
important in modulating and determining the metastatic ability of
CTCs, as well as their progression once secondary tumour
metastases are established.
Cells respond to hypoxia and anoxia differently. A major
response of cells to hypoxia is the induction of hypoxia-inducible
factor 1 (HIF1), which is associated with tumour progression and
metastasis (Liao et al, 2007). Hypoxia-inducible factor 1 is a
heterodimeric protein that is composed of a constitutively
expressed HIF1b subunit and an oxygen (O2)-regulated HIF1a
subunit. Both the stability and transcriptional activity of HIF1 are
negatively regulated by O2-dependent hydroxylation. Under
conditions of higher O2 supply, including normoxia, which are
used in tissue culture studies (O2 levels of 21%), HIF1a is
synthesised and hydroxylated on proline residue 402 and/or 564 by
prolyl hydroxylase domain proteins that use O2 and a-ketogluta-
rate as substrates. Prolyl hydroxylation is required for the binding
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sof the von Hippel–Lindau protein, which then targets HIF1a for
degradation by the proteasome (Epstein et al, 2001). Hypoxia-
inducible factor 1a is also hydroxylated on asparagine residue 803
by Factor Inhibiting HIF-1 (FIH-1), which negatively regulates
the transactivation function (Mahon et al, 2001). With decreasing
O2 levels, the rate of HIF1a hydroxylation is reduced because
of substrate (O2) deprivation. This results in the accumulation
and activation of HIF1a, leading to its dimerisation with HIF1b,
forming HIF1. Hypoxia-inducible factor 1 then induces target
genes that include several adaptive, metastatic, and pro-apoptotic
proteins, such as glycolytic enzymes, glucose transporter protein
type 1 (GLUT1), lysyl oxidase (LOX), and BCL2/adenovirus E1B
19KD protein-interactive protein 3 (BNIP3), respectively (Semenza
et al, 1996; Sowter et al, 2001; Erler et al, 2006).
The anoxia pathway is distinct from the hypoxia–HIF1a
pathway. Recent studies suggest that extremely low levels of O2,
including anoxia, lead to endoplasmic reticulum stress response
(ERSR) and activation of a signal transduction pathway known as
the unfolded protein response, which is HIF1a independent.
Endoplasmic reticulum stress response triggers a complex
programme that results in the reduction of mRNA translation.
However, it specifically increases the translation of factor
activating transcription factor 4 (ATF4) that protects cells from
damaging effects of ER stress (Blais et al, 2004). This same anoxia
pathway can also be activated by nutritional deficiencies such as
glucose and/or amino acid deprivation, and can lead to ERSR and
translational increase of ATF4 (Harding et al, 2000). In addition to
an increase in mRNA translation of factors related to the unfolded
protein response pathway, such as ATF4, cancer cells also respond
to anoxia via other multiple HIF1a-independent pathways,
including the mitogen-activated protein kinase pathway and
protein stabilisation pathways, which result in the induction of
factors such as ATF3 (Ameri et al, 2007; Nemetski and Gardner,
2007) and ATF4 (Ameri et al, 2004; Koditz et al, 2007; Rzymski
et al, 2008).
Although the response of cells to hypoxia has been studied in
detail and the inter-relationships between hypoxia and anoxia
pathways are beginning to emerge, the relationship between CTCs
and tumour hypoxia has not been investigated. In humans, triple
negative (oestrogen receptor negative, progesterone receptor
negative, human epithelial growth factor receptor 2, HER2
negative) breast cancer is an aggressive tumour phenotype that
commonly metastasises and for which there is no targeted therapy.
The aggression of these tumours may be due to a pronounced
hypoxic response (Tan et al, 2009). Using the human triple-
negative breast cancer cell line MDA-MB-231, we generated
orthotopic xenografts in mice that produced CTCs (Eliane et al,
2008) and resulted in lung metastases. Xenografts were profoundly
hypoxic and produced CTCs that could be captured and cultured
using a new technology developed by our laboratory. We examined
the response of CTCs and parental MDA-MB-231 cells to hypoxia
(O2 levels of 0.2%) and compared the ability of both cell types to
develop tumour xenografts in vivo.
MATERIALS AND METHODS
Xenograft generation
NOD.CB17–Prkdc
scid/J mice were purchased from The Jackson
Laboratory (Bar Harbor, ME and Sacramento, CA, USA). Animals
were housed in micro-isolator cages with autoclaved bedding, and
fed autoclaved food and water. All experiments were approved by
Stanford’s Institutional Animal Care and Use Committee and in
accordance with all Administrative Panel on Laboratory Animal
Care (APLAC) regulations at Stanford University and were in
compliance with the National Institutes of Health Guide for Care
and Use of Animals. A total of 20 NOD/SCID (non-obese
diabetic–severe combined immunodeficiency) female mice had
8 10
6 MDA-MB-231 breast cancer cells in 100ml phosphate-
buffered saline (PBS; pH 7.4) plus 100ml of matrigel (BD
Biosciences, San Jose, CA, USA) injected into their left second
mammary fat pads. Control mice were injected with PBS into the
same location. At 55 days after injection, when the average tumour
volume was 1.5cm
3, mice were euthanised for isolation of CTCs.
To assess the tumour formation capacity of CTCs, mammary fat
pads of 10 NOD–SCID mice were injected with a total of 8 10
6
MDA-MB-231 cells or CTCs in a total volume of 200ml, consisting
of 100ml PBS and 100ml matrigel. Tumour size was measured over
a period of 3–6 weeks.
Immunohistochemistry
After the mice were euthanised, their organs and tumours
were fixed in formalin, routinely processed, embedded in paraffin,
and 5-mm sections were placed on glass slides for haematoxylin
& eosin staining and immunohistochemistry (IHC). Microwave
heat-induced epitope retrieval in citrate buffer was used for
IHC as previously described (Higgins and Warnke, 1999). Tumour
and lung sections were stained for the intrinsic marker GLUT1
(ab15309, Abcam, Cambridge, MA, USA), ATF3 (sc-188, Santa
Cruz Biotechnology, Santa Cruz, CA, USA), ATF4 (ab31390,
Abcam), and HIF1a (ab51608, Abcam). At 4h before being
killed, mice were injected through the intraperitoneal route
with the hypoxia marker pimonidazole, and tumour and lung
sections were stained using Hypoxyprobe-1 (NPI, Belmont,
MA, USA).
Isolation of circulating tumour cells
As soon as the mice were euthanised, blood was drawn by means
of a cardiac puncture, recently shown to be the method of choice in
obtaining CTCs from mouse blood (Eliane et al, 2008). Mouse
blood (200–900ml per mouse) was pooled and collected into a
2-ml EDTA tube (BD, Franklin Lakes, NJ, USA). Blood was diluted to
6ml with PBS and labelled with magnetic beads functionalised with
epithelial cell adhesion molecule antibody (Dynabeads, Invitrogen,
Carlsbad, CA, USA). Magnetically labelled blood samples were
transferred to a six-well plate and brought up to a final volume of
10ml using PBS. The magnetically labelled samples were then
processed by the newly developed MagSweeper that isolates CTCs
by multiple rounds of magnetic capture, wash, and release as
previously described (Talasaz et al, 2009). Briefly, magnetic
capturing rods covered by plastic sheaths were robotically swept
through wells containing magnetically labelled mouse blood.
Circulating tumour cells captured on the covered magnetic rods
were transferred and washed in a well containing PBS, and then
released into another well containing PBS by removal of the
magnetic rod from its sheath. After a second cycle of capture,
wash, and release, individual CTCs were microscopically visualised
and transferred to a new six-well plate containing Dulbecco’s
modified Eagle’s medium high glucose (Invitrogen, Carlsbad,
CA, USA) supplemented with 10% (vol/vol) foetal calf serum,
penicillin (100Uml
 1), and streptomycin (100mgml
 1). The
purified CTCs in the six-well plates were cultured in a 5% CO2
incubator at 371C.
Cell culture and hypoxic conditions
Hypoxia was generated using the anaerobic jar HP0011A (Oxoid,
Cambridge, UK and distributed by Remel, Lenexa, KS, USA) and
oxygen levels were monitored using the Analox Mini O2 DII
monitor (Amron International, Vista, CA, USA). Cells were
maintained in Dulbecco’s modified Eagle’s medium high glucose
(Invitrogen) supplemented with 10% (vol/vol) foetal calf serum,
penicillin (100Uml
 1), and streptomycin (100mgml
 1). The
Circulating tumour cells and hypoxia
K Ameri et al
562
British Journal of Cancer (2010) 102(3), 561–569 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
spassage number of CTCs was o7. For hypoxia experiments,
3 10
5 of MDA-MB-231 cells or CTCs were seeded in 5-cm plates
and incubated with 70–80% confluency in the humidified jar.
A gas mixture of 5% CO2/95%N2 was purged into the jar for 20min
until the O2 monitor indicated o0.1% O2, after which additional
gas was purged into the jar for an extra 20min. When experiments
were terminated after 24h, the O2 monitor indicated oxygen levels
of 0.2%.
Colony formation assays
A total of 400 cells were seeded in 5-cm Petri dishes and incubated
for 10 days in either normoxia or hypoxia (n¼5 for each
condition). After 10 days, the colonies were rinsed with PBS and
stained with Giemsa stain-modified solution (Sigma-Aldrich,
St Louis, MO, USA) for 20min. Stained colonies were rinsed with
water, and visually visible colonies, which consisted of approxi-
mately 30 cells, were counted.
Immunoblot
The ATF3, ATF4 and GLUT1 antibodies used for western analysis
were the same as those used for immunostaining. The HIF1a
antibody used for immunoblot analysis was from BD transduction
laboratories (610958, BD Biosciences). CAIX (ab15086) and BNIP3
(ab10433) were from Abcam. The apelin antibody (sc-33804) was
from Santa Cruz Biotechnology. Cell extracts were generated in a
cold room (41C). The cell lysis buffer used for preparing total cell
extracts was a urea-denaturing buffer (6.7M urea, 10mM Tris–HCl
(pH 6.8), 5mM dithiothreitol, 1% sodium dodecyl sulphate, and
10% glycerol) supplemented with Complete mini-protease inhi-
bitor cocktail tablets (Roche Diagnostics, Indianapolis, IN, USA).
Cultured cells were washed rapidly once with ice-cold PBS.
A volume of 100–200ml of urea lysis buffer was added directly
to the plates of cells, scraped into an Eppendorf tube, and
sonicated on ice by using a Vibra Cell ultrasonic processor
(Sonics&Materials, Newton, CT, USA). A detergent-compatible
bicinchoninic acid protein assay kit (Thermo Scientific, Rockford,
IL, USA) was used to estimate the protein concentration of extracts
according to the manufacturer’s protocol. Total cell extracts (30–
60mg per lane) were subjected to reducing sodium dodecyl
sulphate–polyacrylamide gel electrophoresis by first mixing equal
volumes of protein extract and Laemmli sample buffer containing
dithiothreitol and b-mercaptoethanol and running them on a 12%
readymade gel system (Bio-Rad, Hercules, CA, USA). The resolved
proteins were then electroblotted (semidry) onto immune blot
polyvinylidene fluoride membrane (Bio-Rad). Bound antibodies
were detected using the chemiluminescent substrate ECLþPlus
(Amersham Biosciences, Buckinghamshire, UK).
RESULTS
Hypoxic tumour xenograft model
Tumour hypoxia and anoxia have been shown to select for an
aggressive subtype of tumour cells. Such cells would metastasise to
distant organs through the blood stream. We hypothesised that
tumours containing regions of hypoxia and anoxia would give rise
to CTCs that, on the basis of their selection by hypoxia, should be
more aggressive than non-CTCs, and would show an altered
response to hypoxia. To examine this, we first generated a tumour
model containing profound regions of hypoxia and anoxia. We
used the human breast cancer cell line MDA-MB-231 to make
orthotopic xenografts and grew them to an average tumour volume
of 1.5cm
3. Staining for pimonidazole (Figure 1A) and the intrinsic
hypoxia marker GLUT1 (Figure 1B; Airley et al, 2003) confirmed
that all tumours contained hypoxic regions, particularly around
necrotic areas. Although GLUT1 expression and pimonidazole
uptake were more pronounced in tumour cells within perinecrotic
C
Nec Nec
Immunoblot
Nec Nec Nec Nec Nec
i.
ii. 48  h
GLUT1
HIF1
7 days
H N H N
PN  PN PN PN PN
ATF4 ATF3 HIF1 GLUT1 Pimonidazole
A B
Figure 1 Human breast cancer MDA-MB-231cells grown in mammary fat pad of NOD/SCID (Non-obese diabetic–severe combined
immunodeficiency) mice display hypoxic/anoxic regions and express hypoxia and anoxia factors. (A) Tumour sections stained for pimonidazole and
(B) the intrinsic marker GLUT1 ( 10 magnification). (Ci) HIF1a, ATF3, and ATF4 expression in tumours and at the leading edge at sites of local invasion
into surrounding normal tissues (white arrows,  100 magnification). (Cii) Expression of HIF1a and GLUT1 in MDA-MB-231 cells after 7 days of chronic
hypoxia in vitro. N, normoxia; H, hypoxia; Nec, necrotic region; PN, perinecrotic region.
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sregions, the distribution of HIF1a, ATF3, and ATF4 expression
rarely coincided with the pimonidazole and GLUT1 staining
pattern. (Figure 1Ci).
As GLUT1 is an HIF1a target gene, one would expect a similar
pattern of expression. As tumour cells in perinecrotic regions are
more likely to experience chronic hypoxia, we wanted to determine
whether MDA-MB-231 cells subjected to chronic hypoxia in vitro
would also demonstrate disparate induction of HIF1a and GLUT1.
Whereas HIF1a and GLUT1 were both induced in acute hypoxia
(48h), chronic hypoxia (7 days) induced only GLUT1 but not
HIF1a (Figure 1Cii).
Our xenograft model, based on injection of large numbers of
tumour cells (8 10
6) and an extended growth period (55 days),
created profound regions of hypoxia and anoxia in the primary
tumour. Lung metastases developed in all mice. Hypoxia and
anoxia factors expressed in primary tumours were also expressed
in pulmonary metastases (Figure 2).
Distinctive expression of anoxia-induced factors in
hypoxic CTCs
To determine whether CTCs have an altered hypoxia response,
they had to be isolated and grown in culture. We demonstrated
that our MDA-MB-231 xenograft model shed CTCs into mouse
circulation using a new technology that enabled viable human CTC
capture from mouse blood (Talasaz et al, 2009). Magnetic beads
attached to the epithelial cell adhesion molecule antigen on CTCs
appeared as dark clusters of beads on the cell membrane
surrounding translucent cells. In contrast, there were no dark
cell/magnetic bead clusters visible in the blood of control mice.
Instead, only small dark circles representing individual magnetic
beads were observed in control mouse blood (Figure 3Ai).
Captured CTCs were viable and could be subsequently grown in
culture (Figure 3Aii).
It is known that anoxia exerts a selection pressure for aggressive
cells with diminished apoptotic potential. Therefore, anoxia-
selected cells in vivo could enter the blood stream as CTCs and
demonstrate a distinct expression and/or induction of anoxia
factors. To examine this, we compared anoxia factor expression in
CTCs with that of parental MDA-MB-231 cells.
The CTCs demonstrated greater expression and/or induction of
the anoxia-induced factors ATF3 (Figure 3B), ATF4 (Figure 3C and
D), and the ATF4 target gene, ASNS (Figure 3D), than parental
MDA-MB-231 cells. Western blot analysis demonstrated that ATF3
protein was expressed constitutively higher in CTCs compared
with MDA-MB-231 cells, and hypoxia did not dramatically induce
further ATF3 expression as confirmed by densitometry measure-
ments. In contrast, MDA-MB-231 cells induced ATF3 2.4-fold in
hypoxia (Figure 3B). Western blot analysis and densitometry
measurements demonstrated that the ATF4 protein was not
induced in hypoxic MDA-MB 231 cells but was induced 2.4-fold
in hypoxic CTCs (Figure 3C). Western blot analysis showed that
the ATF4 target gene ASNS was also induced to a greater extent in
hypoxic CTCs than in hypoxic MDA-MB-231 cells (Figure 3 D). At
a higher cell passage number (passage 47), CTCs demonstrated
some reversion back to the parental phenotype with respect to
ATF3 expression and increased induction in hypoxia (data not
shown). In summary, CTCs demonstrated an anoxia phenotype by
constitutively expressing and/or inducing anoxia factors at higher
levels compared with parental MDA-MB 231 cells under normoxia
and/or hypoxia.
Distinctive expression of hypoxia-induced factors in CTCs
In addition to anoxia factor expression, tumour aggression has
been related to enhanced expression of hypoxia-induced factors.
Therefore, we questioned whether the hypoxic response of CTCs is
altered. To examine this, we compared the expression of hypoxia
Pimonidazole
Normal lung Lung containing tumour metastases
Metastases
ATF4 ATF3 HIF1α GLUT1
Figure 2 MDA-MB-231 tumours result in pulmonary metastases, which express the hypoxia factors HIF1a and GLUT1, as well as the anoxia factors ATF3
and ATF4. (A) Lungs of xenograft-bearing mice demonstrated metastatic foci, as indicated by the solid arrows on haematoxylin & eosin (H&E) slides. Lungs
from control mice did not contain any tumours ( 100 magnification). (B) Expression of HIF1a, GLUT1, ATF3, and ATF4 in tumour cells in pulmonary
metastatic foci.
Figure 3 Circulating tumour cells (CTCs), isolated and cultured from murine blood, demonstrate a distinct response to hypoxia compared with parental
MDA-MB-231cells. (Ai) Freshly captured CTCs are cells with attached magnetic beads as indicated by white arrows. The magnetic beads are individual small
dark circles, as can be seen in the control; CTCs covered with magnetic beads appear as dark clusters of beads on the cell membrane with translucent
centres, as indicated by white arrows; lack of CTCs in blood samples obtained from six control mice without xenografts. (Aii) The magnetically captured
CTCs in culture on day 10 after capture and after day 60. (B–F) Induction of HIF1a in hypoxic MDA-MB-231 cells and CTCs. (B) Expression of the anoxia
factor ATF3 in CTCs and MDA-MB-231 cells. Graphs demonstrate densitometry measurement of ATF3 expression normalised to actin expression from
three experiments. (C) Induction of the anoxia-induced factor ATF4 in CTCs compared with MDA-MB-231 cells. Graphs demonstrate densitometry
measurements of ATF4 expression normalised to actin expression from three experiments. (D) Expression of ATF4 and its target gene ASNS in CTCs,
compared with parental MDA-MB-231 cells. (E and F) Differences between CTCs and parental MDA-MB-231 cells with respect to induction of HIF1a
target genes. (E) Induction of apelin in hypoxic CTCs compared with parental MDA-MB-231. Hypoxic induction of (E) GLUT1 and (F) CAIX, BNIP3 in
CTCs, compared with parental MDA-MB-231 cells. Experiments were performed at least three or four times with three or four different extracts. N,
normoxia; H, hypoxia.
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sfactors in CTCs and parental MDA-MB-231 cells. Although MDA-
MB-231 cells and CTCs did not differ in their response to hypoxia
with respect to HIF1a induction, CTCs demonstrated a distinct
expression of proteins regulated by HIF1a under hypoxic
conditions. Apelin was induced at greater levels in CTCs than in
parental MDA-MB-231 cells (Figure 3E). In hypoxia, CTCs did
induce GLUT1 (Figure 3E), CAIX and BNIP3 proteins (Figure 3F)
but the inductions were lower than those in parental MDA-MB-231
cells. In summary, CTCs demonstrated an altered response to
hypoxia, showing both pronounced (apelin) and reduced induc-
tion (GLUT1, CAIX, and BNIP3) of specific hypoxia/HIF1-
regulated genes.
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sCTCs grow more aggressively as colonies than
MDA-MB-231 cells in chronic hypoxia and create larger
tumours in vivo, which rapidly result in lung metastasis
The anoxia factors expressed in CTCs are known to be associated
with cell proliferation, aggression, and survival. Therefore, we
questioned whether CTCs possess an enhanced colony formation
capacity in hypoxia. To test this, we performed colony formation
assays. A greater number of colonies was observed with CTCs than
with parental MDA-MB-231 cells, when grown under conditions of
chronic hypoxia for 10 days (Figure 4A). In normoxia, both CTCs
and MDA-MB-231 cells resulted in a similar number of colonies
after 10 days. Results were similar when different numbers of cells
and/or different Petri dish sizes and/or different incubation
periods were used for the colony formation assays. Therefore,
CTCs had a greater colony formation capacity in chronic hypoxia
compared with MDA-MB 231 cells.
The greater clonogenicity under chronic hypoxic conditions
suggested that CTCs were more aggressive than their parental
MDA-MB-231 cells. To examine tumourigenicity and metastatic
potential of CTCs in vivo, we generated 10 orthotopic xenografts
from cultured CTCs and compared tumour growth with that of 10
parental MDA-MB-231 xenografts. Within 3 weeks, two mice
carrying CTC tumour xenografts died. Of the remaining 8 mice
that had CTC xenografts and 10 mice that had MDA-MB-231
xenografts, five were euthanised from each tumour group at week
3. Tumour xenografts in the remaining mice (five with MDA-MB-
231 xenografts and three with CTC xenografts) continued to grow
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Figure 4 Circulating tumour cells (CTCs) demonstrate greater colony formation capabilities in chronic hypoxia compared with parental MDA-MB-231
cells and grow larger and heavier tumours. (A) Colonies grown from CTCs incubated in normoxia and chronic hypoxia compared with colonies grown from
parental MDA-MB-231 cells after 10 days (graph shows mean numbers±s.e.). (Bi) Comparing sizes of xenogafts generated from CTCs with xenografts
generated from MDA-MB-231 cells within 3–6 weeks of growth (graph represents mean volume±s.e., n¼5); (Bii) comparing size and weight of xenografts
from CTCs with xenografts from MDA-MB-231 cells at 3 and 6 weeks (graphs represent mean weight±s.e.). N, normoxia; H, hypoxia.
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sand were measured from week 3 to week 6, after which the mice
were euthanised. As indicated in Figure 4Bi and ii, xenografts
generated from CTCs grew larger and heavier than xenografts from
MDA-MB-231 cells. Pulmonary micrometastases became evident at
week 3 only in mice with xenografts grown from CTCs. By week 6,
mice with parental cell xenografts developed pulmonary meta-
stases. In summary, the more aggressive phenotype of CTCs as
observed in vitro by the expression of anoxia factors and greater
colony formation in chronic hypoxia was also reflected in vivo by
the development of more rapidly growing and metastasising
tumours.
DISCUSSION
Although CTCs have been detected in peripheral blood of cancer
patients, and tumours contain areas of hypoxia and anoxia, which
is prognostically significant in many clinical studies, the response
of CTCs to hypoxia has not been addressed. We have established
an approach to generate and isolate viable CTCs to study their
response to hypoxia. We did this by first generating xenografts
that contained profound areas of hypoxia, and produced lung
metastases. Our xenograft model showing more pronounced
GLUT1 expression and pimonidazole uptake within perinecrotic
regions, and ATF3, ATF4, and HIF1a expressions throughout the
xenografts are in agreement with previous studies of patient
tumours showing that GLUT1 expression was mainly perinecrotic
and did not coincide with HIF1a distribution (Sobhanifar et al,
2005; Vleugel et al, 2005; Tan et al, 2009).
Our hypoxic tumour xenograft model shed CTCs into the
bloodstream, which we isolated and grew in culture. These CTCs
demonstrated an altered response to hypoxia compared with the
parental MDA-MB-231 cells from which they were derived. One
altered response was ATF4 induction seen only in hypoxic CTCs
but not in parental MDA-MB-231 cells. The lack of ATF4 induction
in hypoxic MDA-MB-231 cells confirms our previous results in
which anoxic conditions rather than hypoxic conditions were
shown to be necessary to induce ATF4 (Ameri et al, 2004). The
ATF4 target gene ASNS and the anoxia-induced factor ATF3 were
also expressed at greater levels in CTCs. These results support the
premise that CTCs have a phenotype different than parental MDA-
MB-231 cells. The reason for such an altered phenotype with
respect to expression of anoxia factors remains unclear, but may
be because of tumour tissues being hypoxic in vivo and synchro-
nously exposed to nutrition deprivation/ER stress. In this case, the
hypoxia pathway alone will not be sufficient for the survival, but
additional adaptation responses to nutrition deprivation, such as
ATF4-mediated asparagine synthetase (ASNS) induction, are
necessary for survival (Cui et al, 2007). Therefore, our results
demonstrating that CTCs express the anoxia-induced factors to a
much greater extent in hypoxia compared with parental MDA-MB-
231 cells evoke the possibility that CTCs may have been selected by
a combination of tumour hypoxia and nutrition deprivation/ER
stress in vivo, and hence, there is greater expression of anoxia-
induced and ERSR factors, ATF4 and ASNS, in CTCs.
The mechanism by which CTCs express and/or induce anoxia
factors in hypoxic conditions remains to be elucidated. Previous
publications have suggested that GLUT1 may modulate the ERSR.
For instance, a diminished functional status or lowered expression
level of GLUT1 can induce the ERSR arm of the anoxia pathway
(Li et al, 2007), and hence result in induction of factors related to
the unfolded protein response, such as ATF4. Therefore, it will be
important to uncover the potential involvement of a dysregulated
hypoxia–HIF1 pathway that could result in regulation of anoxia-
induced factors in hypoxic conditions.
Phenotype alterations may be because of the tumour micro-
environment, which contains regions of hypoxia, anoxia, and
nutritional deficiency that exert evolutionary/selective pressure on
tumour cells. Moreover, selected cells that detach from the tumour
and become CTCs will be subjected to additional mechanical stress
from pressure and shear forces of the circulatory system. Cells that
survive such microenvironments may display a more aggressive
phenotype. Greater expression of factors: ATF3, ATF4, and ASNS
suggests an aggressive CTC phenotype associated with cancer
progression and metastasis, and implies a role for HIF1-
independent pathways in CTCs, which could be considered for
future therapeutic interventions. Indeed, our results showed that
CTCs were more aggressive in vitro under chronic hypoxia and
in vivo, which may be due to more pronounced anoxia pathways.
The ATF3 is a gene with a known role in metastasis, and has been
described to induce genes relevant to epithelial-to-mesenchymal
transition (Yin et al, 2008), a histological feature of invading cells
(Guarino et al, 2007). Activating transcription factor 4 is involved
in drug resistance (Igarashi et al, 2007) and is a major factor in
nutrition sensing, regulating the expression of ASNS (Siu et al,
2002). Under conditions of hypoxia and/or glucose deprivation,
cells can switch to ATF4-mediated ASNS expression as a protective
mechanism (Cui et al, 2007). Furthermore, ASNS is also known to
be associated with drug resistance in leukaemia (Williams, 2007)
and oncogenesis triggered by mutated p53 (Scian et al, 2004).
In addition to expressing the anoxia-induced factors at greater
levels, CTCs also demonstrated an altered regulation of hypoxia–
HIF1a target genes. Circulating tumour cells did induce BNIP3,
CAIX, and GLUT1, but the induction of these factors was much
lower than in parental MDA-MB-231 cells. In contrast, induction
of apelin was much higher in CTCs, compared with parental MDA-
MB-231 cells. These results further support that CTCs have an
altered phenotype. The distinctive expression of hypoxia-induced
factors could have implications in the outcome of CTC-mediated
metastasis and in secondary tumour survival and growth. The
significance of greater induction of apelin could be relevant to
tumour growth and metastasis. Apelin is a potent activator of
tumour angiogenesis and is associated with earlier onset of tumour
development and increased tumour growth in vivo (Sorli et al,
2007). The consequences of decreased BNIP3 induction in CTCs
may determine the metastatic potential, as the expression of BNIP3
has been associated with a less-aggressive phenotype in invasive
breast carcinoma (Tan et al, 2007), and a reduction in expression
of BNIP3 has been suggested to be critical for metastasis (Manka
et al, 2005).
The mechanism that accounts for the distinct hypoxia/HIF1
response in CTCs is a subject for further investigation. Activating
transcription factor 4 may downregulate certain HIF1a genes but
upregulate others (Rzymski et al, 2007), and during completion of
this study, it was shown that ATF4 can modulate the hypoxic
induction of HIF1 target genes selectively by inducing CAIX but
not GLUT1 in mouse embryonic fibroblasts, as well as in the
human colon cancer cell line HCT116 and glioblastoma cell line
U373 (van den Beucken et al, 2009). In contrast, we did not
observe greater induction of CAIX in CTCs in which ATF3 and
ATF4 were highly induced by hypoxia. Activating transcription
factor 4 (Ameri and Harris, 2008) and ATF3 (Hai et al, 1999) are
known to be transcriptional activators and repressors, and ATF3 is
known to antagonise ATF4. Thus, whether ATF3 antagonises
ATF4-mediated induction of CAIX in CTCs needs to be
considered. In addition, regulation of CAIX by ATF4 could be
cancer-type specific.
Cross-sectional evaluation of CTC tumours did not show smaller
zones of necrosis that might be expected if all CTCs are assumed to
be resistant to hypoxia. We think that areas of necrosis seen in CTC
tumours are due to greater proliferation in hypoxia, with a rapid
enlargement of tumour mass outgrowing blood/nutrient supply, and
further selection of aggressive cells within a CTC tumour. If such
highly metabolic cells consumed residual oxygen and nutrients, they
would deprive less aggressive populations of critical nutrients and
promote their death. We observed that with higher passage numbers
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phenotype. If some CTC daughter cell populations growing in vivo
also reverted to parental cell behaviour during subcutaneous
tumour growth, these tumour cells could be less resistant to
hypoxia and could affect necrotic zone size.
In summary, we demonstrate that CTCs show an altered
phenotype compared with the parental tumour cells from which
they were derived. We show that CTCs demonstrate a distinct
response to hypoxia in vitro and a greater aggression in vivo.
Our study also shows that the circulating cells captured from
blood by the MagSweeper are indeed cancer cells in that they
produce tumours in mice that metastasise. Our experimental
system may be applied to test drug efficacy in targeting CTCs for
the prevention of metastases as suggested by Bondareva et al
(2009). Our approach and data provide a foundation to investigate
selective factors associated with CTC aggressiveness and enable the
identification of additional therapeutic targets related to tumour
hypoxia and CTCs.
ACKNOWLEDGEMENTS
This study was supported in part by National Institutes of Health
grant R01GM085601 (SSJ), the California Breast Cancer Research
Program of the University of California, Grant Number 11IB-0175
(SSJ), the John and Marva Warnock Cancer Research Fund, and
the Rachleff family fund. KA was supported by fellowship funds
from Bernard and Susan Liautaud and the Stanford University
School of Medicine Dean’s Scholar Award.
Conflict of interest
Drs Stefanie Jeffrey and Ashley Powell are co-inventors of the
MagSweeper CTC isolation technology used in this study. They
can receive royalties from this invention through Stanford, but
Dr Jeffrey has donated her royalties to support student pro-
grammes at The Jackson Laboratory, a non-profit biomedical
research institution.
REFERENCES
Airley RE, Loncaster J, Raleigh JA, Harris AL, Davidson SE, Hunter RD,
West CM, Stratford IJ (2003) GLUT-1 and CAIX as intrinsic markers of
hypoxia in carcinoma of the cervix: relationship to pimonidazole
binding. Int J Cancer 104: 85–91
Ameri K, Hammond EM, Culmsee C, Raida M, Katschinski DM, Wenger
RH, Wagner E, Davis RJ, Hai T, Denko N, Harris AL (2007) Induction of
activating transcription factor 3 by anoxia is independent of p53 and the
hypoxic HIF signalling pathway. Oncogene 26: 284–289
Ameri K, Harris AL (2008) Activating transcription factor 4. Int J Biochem
Cell Biol 40: 14–21
Ameri K, Lewis CE, Raida M, Sowter H, Hai T, Harris AL (2004)
Anoxic induction of ATF-4 through HIF-1-independent
pathways of protein stabilization in human cancer cells. Blood 103:
1876–1882
Blais JD, Filipenko V, Bi M, Harding HP, Ron D, Koumenis C, Wouters BG,
Bell JC (2004) Activating transcription factor 4 is translationally
regulated by hypoxic stress. Mol Cell Biol 24: 7469–7482
Bondareva A, Downey CM, Ayres F, Liu W, Boyd SK, Hallgrimsson B, Jirik
FR (2009) The lysyl oxidase inhibitor, beta-aminopropionitrile,
diminishes the metastatic colonization potential of circulating breast
cancer cells. PLoS One 4: e5620
Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR,
Dewhirst MW (1996) Tumor oxygenation predicts for the likelihood of
distant metastases in human soft tissue sarcoma. Cancer Res 56: 941–943
Cui H, Darmanin S, Natsuisaka M, Kondo T, Asaka M, Shindoh M,
Higashino F, Hamuro J, Okada F, Kobayashi M, Nakagawa K,
Koide H (2007) Enhanced expression of asparagine synthetase under
glucose-deprived conditions protects pancreatic cancer cells from
apoptosis induced by glucose deprivation and cisplatin. Cancer Res 67:
3345–3355
Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, Jackson S,
Hortobagyi GN, Fritsche H, Cristofanilli M (2008) Circulating tumor cells
in metastatic breast cancer: from prognostic stratification to modifica-
tion of the staging system? Cancer 113: 2422–2430
Eliane JP, Repollet M, Luker KE, Brown M, Rae JM, Dontu G, Schott AF,
Wicha M, Doyle GV, Hayes DF, Luker GD (2008) Monitoring serial
changes in circulating human breast cancer cells in murine xenograft
models. Cancer Res 68: 5529–5532
Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O’Rourke J, Mole DR,
Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N,
Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW,
Schofield CJ, Ratcliffe PJ (2001) C. elegans EGL-9 and mammalian
homologs define a family of dioxygenases that regulate HIF by prolyl
hydroxylation. Cell 107: 43–54
Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, Chi JT,
Jeffrey SS, Giaccia AJ (2006) Lysyl oxidase is essential for hypoxia-
induced metastasis. Nature 440: 1222–1226
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW,
Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished
apoptotic potential in solid tumours. Nature 379: 88–91
Guarino M, Rubino B, Ballabio G (2007) The role of epithelial-
mesenchymal transition in cancer pathology. Pathology 39: 305–318
Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell
127: 679–695
Hai T, Wolfgang CD, Marsee DK, Allen AE, Sivaprasad U (1999) ATF3 and
stress responses. Gene Expr 7: 321–335
Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, Ron D (2000)
Regulated translation initiation controls stress-induced gene expression
in mammalian cells. Mol Cell 6: 1099–1108
Higgins JP, Warnke RA (1999) CD30 expression is common in mediastinal
large B-cell lymphoma. Am J Clin Pathol 112: 241–247
Igarashi T, Izumi H, Uchiumi T, Nishio K, Arao T, Tanabe M, Uramoto H,
Sugio K, Yasumoto K, Sasaguri Y, Wang KY, Otsuji Y, Kohno K (2007)
Clock and ATF4 transcription system regulates drug resistance in human
cancer cell lines. Oncogene 26: 4749–4760
Koditz J, Nesper J, Wottawa M, Stiehl DP, Camenisch G, Franke C,
Myllyharju J, Wenger RH, Katschinski DM (2007) Oxygen-dependent
ATF-4 stability is mediated by the PHD3 oxygen sensor. Blood 110:
3610–3617
Li J, Wang XM, Wang Q, Yang M, Feng XC, Shen ZH (2007) Down-
regulation of N-acetylglucosaminyltransferase-V induces ER stress by
changing glycosylation and function of GLUT1. Arch Biochem Biophys
463: 102–109
Liao D, Corle C, Seagroves TN, Johnson RS (2007) Hypoxia-inducible
factor-1alpha is a key regulator of metastasis in a transgenic model of
cancer initiation and progression. Cancer Res 67: 563–572
Mahon PC, Hirota K, Semenza GL (2001) FIH-1: a novel protein that
interacts with HIF-1alpha and VHL to mediate repression of HIF-1
transcriptional activity. Genes Dev 15: 2675–2686
Manka D, Spicer Z, Millhorn DE (2005) Bcl-2/adenovirus E1B 19-kDa
interacting protein-3 knockdown enables growth of breast cancer
metastases in the lung, liver, and bone. Cancer Res 65: 11689–11693
Nemetski SM, Gardner LB (2007) Hypoxic regulation of Id-1 and activation
of the unfolded protein response are aberrant in neuroblastoma. J Biol
Chem 282: 240–248
Rzymski T, Paantjens A, Bod J, Harris AL (2007) American Association
Cancer Research, AACR. Abstract Number 4596
Rzymski T, Paantjens A, Bod J, Harris AL (2008) Multiple pathways are
involved in the anoxia response of SKIP3 including HuR-regulated RNA
stability, NF-kappaB and ATF4. Oncogene 27: 4532–4543
Scian MJ, Stagliano KE, Deb D, Ellis MA, Carchman EH, Das A, Valerie K,
Deb SP, Deb S (2004) Tumor-derived p53 mutants induce oncogenesis by
transactivating growth-promoting genes. Oncogene 23: 4430–4443
Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P,
Giallongo A (1996) Hypoxia response elements in the aldolase A, enolase
1, and lactate dehydrogenase A gene promoters contain essential binding
sites for hypoxia-inducible factor 1. J Biol Chem 271: 32529–32537
Siu F, Bain PJ, LeBlanc-Chaffin R, Chen H, Kilberg MS (2002) ATF4 is a
mediator of the nutrient-sensing response pathway that activates the
human asparagine synthetase gene. J Biol Chem 277: 24120–24127
Circulating tumour cells and hypoxia
K Ameri et al
568
British Journal of Cancer (2010) 102(3), 561–569 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sSobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P (2005) Reduced
expression of hypoxia-inducible factor-1alpha in perinecrotic regions of
solid tumors. Cancer Res 65: 7259–7266
Sorli SC, Le Gonidec S, Knibiehler B, Audigier Y (2007) Apelin is a potent
activator of tumour neoangiogenesis. Oncogene 26: 7692–7699
Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL (2001) HIF-1-
dependent regulation of hypoxic induction of the cell death factors
BNIP3 and NIX in human tumors. Cancer Res 61: 6669–6673
Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, Yu W, Xiao W,
Davis MM, Pease RF, Mindrinos MN, Jeffrey SS, Davis RW (2009)
Isolating highly enriched populations of circulating epithelial cells and
other rare cells from blood using a magnetic sweeper device. Proc Natl
Acad Sci USA 106: 3970–3975
Tan EY, Campo L, Han C, Turley H, Pezzella F, Gatter KC, Harris AL, Fox
SB (2007) BNIP3 as a progression marker in primary human breast
cancer; opposing functions in in situ versus invasive cancer. Clin Cancer
Res 13: 467–474
Tan EY, Yan M, Campo L, Han C, Takano E, Turley H, Candiloro I,
Pezzella F, Gatter KC, Millar EK, O’Toole SA, McNeil CM, Crea P,
Segara D, Sutherland RL, Harris AL, Fox SB (2009) The key hypoxia
regulated gene CAIX is upregulated in basal-like breast tumours
and is associated with resistance to chemotherapy. Br J Cancer 100:
405–411
van den Beucken T, Koritzinsky M, Niessen H, Dubois L, Savelkouls K,
Mujcic H, Jutten B, Kopacek J, Pastorekova S, van der Kogel AJ, Lambin
P, Voncken W, Rouschop KM, Wouters BG (2009) Hypoxia-induced
expression of carbonic anhydrase 9 is dependent on the unfolded protein
response. J Biol Chem 284: 24204–24212
Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M,
Aarbodem Y, van Tinteren H, Harris AL, van Diest PJ, van der Wall E
(2005) Differential prognostic impact of hypoxia induced and diffuse
HIF-1alpha expression in invasive breast cancer. J Clin Pathol 58:
172–177
Williams DA (2007) A new mechanism of leukemia drug resistance? N Engl
J Med 357: 77–78
Yin X, Dewille JW, Hai T (2008) A potential dichotomous role of ATF3, an
adaptive-response gene, in cancer development. Oncogene 27: 2118–2127
Zhang L, Hill RP (2004) Hypoxia enhances metastatic efficiency by up-
regulating Mdm2 in KHT cells and increasing resistance to apoptosis.
Cancer Res 64: 4180–4189
This work is licensed under the Creative Commons
Attribution-NonCommercial-Share Alike 3.0 License.
To view a copy of this license, visit http://creativecommons.org/
licenses/by-nc-sa/3.0/
Circulating tumour cells and hypoxia
K Ameri et al
569
British Journal of Cancer (2010) 102(3), 561–569 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s